Denali Therapeutics (DNLI) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a buy rating in a research note published on Tuesday. They currently have $21.00 price target on the stock.

According to Zacks, “Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. “

How to Become a New Pot Stock Millionaire

Several other analysts also recently weighed in on the stock. Morgan Stanley started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an overweight rating and a $25.00 price target for the company. Evercore ISI started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an outperform rating and a $23.00 price target for the company. Goldman Sachs started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued a neutral rating for the company. Finally, JPMorgan Chase started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an overweight rating and a $24.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $23.25.

NASDAQ DNLI opened at $18.11 on Tuesday. The firm has a market cap of $1,783.77 and a PE ratio of -3.07. Denali Therapeutics has a 52-week low of $14.72 and a 52-week high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Monday, March 19th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.47). research analysts predict that Denali Therapeutics will post -0.56 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Landscape Capital Management L.L.C. bought a new stake in Denali Therapeutics in the fourth quarter worth $166,000. MYDA Advisors LLC purchased a new position in shares of Denali Therapeutics in the fourth quarter valued at about $188,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Denali Therapeutics in the fourth quarter valued at about $237,000. Wolverine Asset Management LLC purchased a new position in shares of Denali Therapeutics in the fourth quarter valued at about $249,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Denali Therapeutics in the fourth quarter valued at about $621,000. 60.98% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/denali-therapeutics-dnli-stock-rating-upgraded-by-zacks-investment-research.html.

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply